Machine-learning screening identifies bacterial-selective membrane-active compounds
The June 2026 bioRxiv version describes an initial machine-learning-guided screen of ZINC20 compounds balancing predicted antibacterial activity, mammalian-cell toxicity, and mechanism-of-action novelty. Among 61 purchased candidates, six showed partial growth inhibition; 49 were non-toxic to HepG2 cells at 50 μM. Flow cytometry indicated membrane disruption for four of the six initial active hits and membrane depolarization for two. A September version reports additional screening and revised models; its expanded results are not attributed to the June version here. The study does not report a novel protein target or clinical antibiotic.
Technology: Graph-convolutional neural networks for antibacterial activity/toxicity with XGBoost mechanism-of-action classification and novelty filtering
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The June 2026 v1 reports that 61 purchased candidates were tested, six showed partial growth inhibition, and 49/61 were non-toxic to HepG2 cells at 50 μM. Flow cytometry indicated membrane integrity disruption for four initial active hits and membrane depolarization for two.
- Still unknown: The initial work does not report a novel protein target and is limited to the stated bacterial assays and HepG2 toxicity concentration. The September version adds expanded screening and revised analyses; those later results are not attributed to the June v1.
- AI role: Learned activity and toxicity models, together with a mechanism-novelty classifier, prioritized compounds for purchase and experimental testing.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13278111/ · https://pubmed.ncbi.nlm.nih.gov/42327090/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PMC-indexed full text for the June bioRxiv v1, primary PubMed preprint abstract/metadata, and primary PMC/PubMed metadata for the later September version to distinguish version-specific results..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.